Research
Smad4 haploinsufficiency: a matter of dosage
-
* Corresponding author: Riccardo Fodde r.fodde@erasmusmc.nl
1 Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
2 Department of Biochemistry, Erasmus MC, Rotterdam, The Netherlands
3 Newcastle Bowel Cancer Research Collaborative, Hunter Medical Research Institute, John Hunter Hospital and The University of Newcastle, Newcastle, Australia
4 Division of Pathology HUSLAB and Haartman Institute, Helsinki University Central Hospital, Helsinki, Finland
5 Department of Medical Genetics, HUSLAB and Haartman Institute, Helsinki University Central Hospital, Finland
6 Genome Scale Biology Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
7 Current address: IFOM -The FIRC Institute of Molecular Oncology, IFOM-IEO Campus, Milano, Italy
8 Current address: Department of Experimental Oncology, European Institute of Oncology (IEO), IFOM-IEO Campus, Milano, Italy
PathoGenetics 2008, 1:2 doi:10.1186/1755-8417-1-2
Published: 3 November 2008Additional files
Additional file 1:
Supplementary Table 1. List of 64 functionally annotated genes differentially express in Smad4+/E6sad and Smad4E6sad/E6sad ES cell lines. Expression profiling values are expressed as absolute fold change values when compared to Smad4+/+ ES cells.
Format: DOC Size: 60KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional file 2:
Supplementary Table 2. Ingenuity Pathway Analysis of the 64 functionally annotated genes differentially expressed (denoted as "focus molecules" in bold) in Smad4+/E6sad and Smad4E6sad/E6sad ES cell lines. The column denoted as "Top Functions" describe the gene ontology groups to which the genes encompassed in a given Ingenuity Network belong. Only the top 4 networks with the most significant scores are included.
Format: DOC Size: 27KB Download file
This file can be viewed with: Microsoft Word Viewer